NeuBase Therapeutics Inc. [NASDAQ: NBSE] gained 21.83% on the last trading session, reaching $8.65 price per share at the time. The company report on January 11, 2021 that NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference.
NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview during the H.C. Wainwright Virtual BioConnect Conference, which is being held from January 11 – 14, 2021. A webcast of the on-demand presentation will be available beginning at 6:00 a.m. Eastern Time and archived on the NeuBase website, www.neubasetherapeutics.com.
About NeuBase TherapeuticsNeuBase is accelerating the genetic revolution using a new class of synthetic medicines. NeuBase’s designer PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com.
NeuBase Therapeutics Inc. represents 23.16 million in outstanding shares, while the company has a total market value of $207.77 million with the latest information. NBSE stock price has been found in the range of $6.92 to $8.94.
If compared to the average trading volume of 205.76K shares, NBSE reached a trading volume of 1220940 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about NeuBase Therapeutics Inc. [NBSE]:
RBC Capital Mkts have made an estimate for NeuBase Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on June 16, 2020. The new note on the price target was released on February 07, 2020, representing the official price target for NeuBase Therapeutics Inc. stock.
The Average True Range (ATR) for NeuBase Therapeutics Inc. is set at 0.62 The Price to Book ratio for the last quarter was 6.41, with the Price to Cash per share for the same quarter was set at 1.33.
Trading performance analysis for NBSE stock
NeuBase Therapeutics Inc. [NBSE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.42. With this latest performance, NBSE shares gained by 2.61% in over the last four-week period, additionally plugging by 8.94% over the last 6 months – not to mention a rise of 28.34% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NBSE stock in for the last two-week period is set at 62.55, with the RSI for the last a single of trading hit 68.77, and the three-weeks RSI is set at 58.57 for NeuBase Therapeutics Inc. [NBSE]. The present Moving Average for the last 50 days of trading for this stock 7.84, while it was recorded at 7.54 for the last single week of trading, and 8.19 for the last 200 days.
NeuBase Therapeutics Inc. [NBSE]: A deeper dive into fundamental analysis
Return on Total Capital for NBSE is now -82.09, given the latest momentum, and Return on Invested Capital for the company is -84.14. Return on Equity for this stock declined to -84.14, with Return on Assets sitting at -74.01. When it comes to the capital structure of this company, NeuBase Therapeutics Inc. [NBSE] has a Total Debt to Total Equity ratio set at 0.44. Additionally, NBSE Total Debt to Total Capital is recorded at 0.44, with Total Debt to Total Assets ending up at 0.40.
Reflecting on the efficiency of the workforce at the company, NeuBase Therapeutics Inc. [NBSE] managed to generate an average of -$1,158,968 per employee.NeuBase Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.40 and a Current Ratio set at 10.40.
NeuBase Therapeutics Inc. [NBSE]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, NeuBase Therapeutics Inc. posted -0.26/share EPS, while the average EPS was predicted by analysts to be reported at -0.32/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 18.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NBSE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for NeuBase Therapeutics Inc. go to 4.00%.
An analysis of insider ownership at NeuBase Therapeutics Inc. [NBSE]
There are presently around $48 million, or 32.20% of NBSE stock, in the hands of institutional investors. The top three institutional holders of NBSE stocks are: GREENLIGHT CAPITAL INC with ownership of 2,027,027, which is approximately 6.505% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 916,553 shares of the stock with an approximate value of $6.51 million in NBSE stocks shares; and BLACKROCK INC., currently with $6.43 million in NBSE stock with ownership of nearly -2.825% of the company’s market capitalization.
Positions in NeuBase Therapeutics Inc. stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 25 institutional holders increased their position in NeuBase Therapeutics Inc. [NASDAQ:NBSE] by around 1,861,013 shares. Additionally, 28 investors decreased positions by around 986,498 shares, while 10 investors held positions by with 3,911,434 shares. The mentioned changes placed institutional holdings at 6,758,945 shares, according to the latest SEC report filing. NBSE stock had 12 new institutional investments in for a total of 516,168 shares, while 12 institutional investors sold positions of 584,162 shares during the same period.